Description
Product Characteristics:
Activation of TAL1 characterizes up to 60 % of cases of human T cell acute lymphoblastic leukemia, making it the most frequent gain-of-function mutation observed in this disorder. TAL1 (also designated SCL) is a serine phosphoprotein and basic helix-loop-helix transcription factor known to regulate embryonic hematopoiesis. This transcription factor binds as a heterodimer with E2A and HEB/HTF4 to a nucleotide sequence motif termed the E-box. In addition, leukemogenesis is accelerated dramatically by transgenic co-expression of TAL1 and the catalytic subunit of casein kinase IIalpha, a serine/ threonine protein kinase known to modulate the activity of other bHLH transcription factors.
Synonyms: bHLHa17, Class A basic helix-loop-helix protein 17, SCL antibody, Stem cell protein, T cell acute lymphocytic leukemia 1, T cell acute lymphocytic leukemia 1 protein, T cell leukemia/lymphoma 5 protein, T-cell acute lymphocytic leukemia protein 1, T-cell leukemia/lymphoma protein 5, Tal 1, Tal 1 product, TAL 1 protein, TAL-1, tal1, TAL1_HUMAN, TCL 5, TCL5.
Target Information: Transcription factor that acts synergistically with lmo2 and gata1 to specify embryonic dorsal mesoderm to a hematopoietic fate